logo-loader
viewVolitionRx

VolitionRx signs distribution agreement with Active Motif to sell research-use-only kits

The kits are based on the same Nu.Q immunoassay technology as VolitionRx's cancer screening panels

A scientist in a clean room
VolitionRx's cancer-screening tools have become quite popular

VolitionRx Ltd (NYSEMKTS:VNRX), the cancer test specialist, has entered into a groundbreaking sales and distribution partnership with a rival life sciences group Active Motif that will pave the way for the sale of a range of research-use-only (RUO) kits based on its proprietary Nucleosomics technology starting in June.

These research-use-only kits are based on VolitionRx’s technology platform of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid- an indication that disease is present.

Once they are distributed with the help of Active Motif, these RUO kits will provide researchers with new ways to explore changes in gene expression across different diseases from clinical samples.

The RUO kits are based on the same Nu.Q immunoassay technology as Volition's cancer screening panels and may be used to investigate a variety of clinical questions beyond Volition's core focus in cancer biomarkers.

READ: VolitionRx hails interim results of Danish trial for screening colorectal cancer

“This is a fantastic opportunity for Volition and we expect that it will provide an additional revenue stream beyond that from the expected commercialization of our blood-based tests for cancer,” said Cameron Reynolds, Volition’s chief executive officer, in a press release.

VolitionRx’s cancer-screening tools have become quite popular, particularly in the area of colorectal cancer.

In the US, Volition is taking part in what is believed to be the largest ever colorectal cancer screening study in collaboration with the National Cancer Institute's Early Detection Research Network with a cohort of over 13,500 subjects.

Collection is underway and is expected to be completed in 2020. The idea is to build on the European studies to refine test performance and to present final data to the FDA before the study is completed.

Quick facts: VolitionRx

Price: 4.82 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $198.61 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

VolitionRx acquires epigenetic reagent company Octamer GmbH

VolitionRx Limited's (NYSEAMERICAN:VNRX) Cameron Reynolds talks through the rationale for its acquisition of epigenetic reagent company Octamer GmbH. Reynolds says they're paying around €650,000 euros ($725,000) in cash and stock and the deal is expected to close in January 2020. 

on 12/20/2019

2 min read